Overview

* ImmunityBio Q2 2025 revenue rises 60% to $26.4 mln, beating analyst expectations

* Company's revenue growth driven by ANKTIVA sales in BCG-unresponsive NMIBC

* ImmunityBio ( IBRX ) ends Q2 with $153.7 mln in cash, plus $80 mln equity financing

Result Drivers

* ANKTIVA SALES - 60% revenue increase in Q2 2025 driven by strong sales of ANKTIVA in BCG-unresponsive NMIBC

* UNIT GROWTH - 246% increase in ANKTIVA unit sales volume in 1H 2025 compared to 2H 2024 post J-code approval

* FINANCIAL POSITION - $80 mln equity financing in July 2025 strengthens cash reserves, enhancing financial stability

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $26.42 $22.80

Revenue mln mln (5

Analysts

)

Q2 Net -$92.57

Income mln

Q2 -$71.28

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Immunitybio Inc ( IBRX ) is $8.00, about 69.9% above its August 4 closing price of $2.41

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)